Phase 2 Asthma Trial, Recruiting (NCT07241546)

Phase 2 Asthma Trial, Recruiting NCT07241546 Sponsor: Arrowhead Pharmaceuticals Condition: Asthma

Printed from Voxsanity (voxsanity.com.au) — NCT07241546 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Asthma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have mild asthma that is currently stable, with lung function measured at 70% or more of what is expected for someone of their age and size
People who have a confirmed allergy, shown by a positive skin prick test done at the start of the study
People who are able and willing to take part in breathing tests and other study-related tasks
People who are able to become pregnant must agree to use a highly effective form of contraception as well as a condom throughout the study, and for at least 90 days after the study ends or after the last dose of the study treatment, whichever comes later

Who may not be able to join:

People who have been diagnosed with another significant lung condition in addition to asthma
People who are currently using steroid medicines, medicines that suppress the immune system, or anti-inflammatory medicines that could affect the study tests, or who regularly use any other medicine to treat allergic asthma
People who have a past or current health condition that makes a specific breathing test (called a methacholine challenge) unsafe for them (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 20 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 626-304-3400

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07241546

Sponsor: Arrowhead Pharmaceuticals

Phase: Phase 2

Status: Recruiting

Condition: Asthma

Trial contact: 626-304-3400

More information: https://clinicaltrials.gov/study/NCT07241546

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have mild asthma that is currently stable, with lung function measured at 70% or more of what is expected for someone of their age and size
People who have a confirmed allergy, shown by a positive skin prick test done at the start of the study
People who are able and willing to take part in breathing tests and other study-related tasks
People who are able to become pregnant must agree to use a highly effective form of contraception as well as a condom throughout the study, and for at least 90 days after the study ends or after the last dose of the study treatment, whichever comes later

Who may not be able to join:

People who have been diagnosed with another significant lung condition in addition to asthma
People who are currently using steroid medicines, medicines that suppress the immune system, or anti-inflammatory medicines that could affect the study tests, or who regularly use any other medicine to treat allergic asthma
People who have a past or current health condition that makes a specific breathing test (called a methacholine challenge) unsafe for them (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 20 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Arrowhead Pharmaceuticals

Registry

ClinicalTrials.gov

Start date

30 March 2026

Est. completion

1 December 2027

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Change from Baseline Over Time in Maximum Area of Reactance

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov